Literature DB >> 9561376

The significance of endotoxin release in experimental and clinical sepsis in surgical patients--evidence for antibiotic-induced endotoxin release?

R G Holzheimer1.   

Abstract

Sepsis and peritonitis remain a serious challenge for surgical patients, despite improvement in surgical therapy and intensive care and the introduction of new powerful antibiotics. Recent in vitro studies revealed the potential of certain antibiotics, e.g. penicillin-binding protein (PBP) 3-specific antibiotics, to cause antibiotic-induced endotoxin release. Other types of antibiotics, e.g., PBP 2-specific antibiotics, were associated with no or less endotoxin release. Further in vitro experiments and investigations in animals support the hypothesis of antibiotic-induced endotoxin release, but there is little clinical evidence. The clinical significance of endotoxin is subject of open dispute with many pro's and contra's. Endotoxin, although an important trigger, may not be the only factor to induce cytokine release, e.g., peptidoglycans were able to stimulate cells to release cytokines. Gram-positive pathogens have gained more importance in clinical sepsis and may not be sufficiently reflected in current clinical studies. The hypothesis that neutralization of endotoxin and pro-inflammatory cytokines is beneficial in sepsis was seriously challenged by the results of recent clinical and experimental studies. The better understanding of mechanisms in endotoxin-induced cell activation and cell, cell-receptor and soluble receptor interactions led to new treatment options. Recent reports on the complex pathogenesis of peritonitis and the detection of pathogen-related factors with intraperitoneal immune response may have implications on clinical studies investigating the potential of new compounds and the effect of antibiotics on endotoxin release. However, only few reports are available on the clinical significance of antibiotic-induced endotoxin release, and association of endotoxin release with pathogens, mortality or alteration of physiological parameters were not observed. With regard to the particulars of these studies, e.g., a small study population or low mortality rate, mortality may not be an ideal outcome parameter for these studies. There is clinical evidence for antibiotic-induced endotoxin release. However, the need for well-designed and performed studies using newly developed monitoring devices in intensive care therapy is obvious.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9561376     DOI: 10.1007/BF02767765

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  88 in total

1.  Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study.

Authors:  A S Dofferhoff; J H Nijland; H G de Vries-Hospers; P O Mulder; J Weits; V J Bom
Journal:  Scand J Infect Dis       Date:  1991

2.  Endotoxin and lipid A stimulate proliferation of human T cells in the presence of autologous monocytes.

Authors:  T Mattern; A Thanhäuser; N Reiling; K M Toellner; M Duchrow; S Kusumoto; E T Rietschel; M Ernst; H Brade; H D Flad
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

3.  Evaluation of endotoxiuria for diagnosis of urinary tract infection after major surgical procedures.

Authors:  D Berger; E Boelke; M Seidelmann; H G Beger
Journal:  Clin Chim Acta       Date:  1996-01-31       Impact factor: 3.786

Review 4.  Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation?

Authors:  W L Biffl; E E Moore; F A Moore; V M Peterson
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

5.  Correlation between Acute Physiology and Chronic Health Evaluation (APACHE) III score and immunological parameters in critically ill patients with sepsis.

Authors:  M A Rogy; H S Oldenburg; S Coyle; R Trousdale; L L Moldawer; S F Lowry
Journal:  Br J Surg       Date:  1996-03       Impact factor: 6.939

6.  A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides.

Authors:  F E Di Padova; H Brade; G R Barclay; I R Poxton; E Liehl; E Schuetze; H P Kocher; G Ramsay; M H Schreier; D B McClelland
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

7.  Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia.

Authors:  T van der Poll; S J van Deventer; H ten Cate; M Levi; J W ten Cate
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

8.  Delayed antibiotic-induced lysis of Escherichia coli in vitro is correlated with enhancement of LPS release.

Authors:  C Van Den Berg; A J de Neeling; C S Schot; W N Hustinx; J Wemer; D J de Wildt
Journal:  Scand J Infect Dis       Date:  1992

9.  Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis.

Authors:  G J Bagby; K J Plessala; L A Wilson; J J Thompson; S Nelson
Journal:  J Infect Dis       Date:  1991-01       Impact factor: 5.226

10.  Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial.

Authors:  M E Astiz; E C Rackow; J G Still; S T Howell; A Cato; K B Von Eschen; J T Ulrich; J A Rudbach; G McMahon; R Vargas
Journal:  Crit Care Med       Date:  1995-01       Impact factor: 7.598

View more
  12 in total

1.  Hypothesis: is a failure to prevent bacteriolysis and the synergy among microbial and host-derived pro-inflammatory agonists the main contributory factors to the pathogenesis of post-infectious sequelae?

Authors:  I Ginsburg
Journal:  Inflammation       Date:  2001-02       Impact factor: 4.092

2.  Bacterial cell wall compounds as promising targets of antimicrobial agents I. Antimicrobial peptides and lipopolyamines.

Authors:  Guillermo Martínez de Tejada; Susana Sánchez-Gómez; Iosu Rázquin-Olazaran; Ina Kowalski; Yani Kaconis; Lena Heinbockel; Jörg Andrä; Tobias Schürholz; Mathias Hornef; Aline Dupont; Patrick Garidel; Karl Lohner; Thomas Gutsmann; Sunil A David; Klaus Brandenburg
Journal:  Curr Drug Targets       Date:  2012-08       Impact factor: 3.465

3.  Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients.

Authors:  Usama Feroze; Kamyar Kalantar-Zadeh; Kevin A Sterling; Miklos Z Molnar; Nazanin Noori; Debbie Benner; Vallabh Shah; Rama Dwivedi; Kenneth Becker; Csaba P Kovesdy; Dominic S Raj
Journal:  J Ren Nutr       Date:  2011-08-31       Impact factor: 3.655

4.  Effect of empiric antibiotic treatment on plasma endotoxin activity in septic patients.

Authors:  F Mignon; M Piagnerelli; M Van Nuffelen; J L Vincent
Journal:  Infection       Date:  2014-01-28       Impact factor: 3.553

5.  Bactericidal antibiotics temporarily increase inflammation and worsen acute kidney injury in experimental sepsis.

Authors:  Zhi-Yong Peng; Hong-Zhi Wang; Nattachai Srisawat; Xiaoyan Wen; Thomas Rimmelé; Jeffery Bishop; Kai Singbartl; Raghavan Murugan; John A Kellum
Journal:  Crit Care Med       Date:  2012-02       Impact factor: 7.598

6.  Effect of ceftazidime on systemic cytokine concentrations in rats.

Authors:  K M Alkharfy; J A Kellum; R F Frye; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Drotrecogin alfa (activated).

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria.

Authors:  C A Gogos; A Skoutelis; A Lekkou; E Drosou; I Starakis; M N Marangos; H P Bassaris
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Translocated LPS might cause endotoxin tolerance in circulating monocytes of cystic fibrosis patients.

Authors:  Rosa del Campo; Eriel Martínez; Carlos del Fresno; Raquel Alenda; Vanesa Gómez-Piña; Irene Fernández-Ruíz; María Siliceo; Teresa Jurado; Victor Toledano; Francisco Arnalich; Francisco García-Río; Eduardo López-Collazo
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

10.  Multi-drug strategies are necessary to inhibit the synergistic mechanism causing tissue damage and organ failure in post infectious sequelae.

Authors:  I Ginsburg
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 5.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.